Tactile Medical Q3 revenue rises 7% to $91.9 million; net income falls to $7.2 million
Tactile Medical reported third-quarter 2026 results on November 2, 2026. Revenue and lymphedema sales grew year over year, but net income and diluted earnings per share fell as operating expenses rose 13%. The company raised its full-year 2026 Adjusted EBITDA guidance by $1 million at both ends of the range and kept its revenue guidance unchanged.
Key points
- Total revenue rose 7% year over year to $91.9 million; lymphedema sales rose 13% to $81.8 million, while airway clearance sales fell 25% to $10.0 million.
- Net income was $7.2 million, or $0.31 per diluted share, down from $8.2 million, or $0.36, in Q3 2025.
- Full-year 2026 Adjusted EBITDA guidance is now $50 million to $52 million, up from $49 million to $51 million; revenue guidance of $360 million to $366 million was unchanged.
- The company repurchased $6.2 million of stock in the quarter, leaving $12.5 million under its $25.0 million program, which expires November 3, 2027.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.